CompaniesOtherUpdated Oct 16, 2026
Acta Pharmaceuticals
Private. Acta Pharmaceuticals, Inc. is building on four decades of discoveries led by renowned neuroscientist Dr. Rudolph (Rudy) Tanzi to develop new therapies for early intervention and Alzheimer’s prevention.
- Last round
- $24M Seed
- Backed by
- Not recorded
- Launched
- 2022
- People
- 6
Overview
Updated Oct 16, 2026
Every fact carries a numbered source. Where we can't source something, it says so.
Identity fields from the company record are sourced where a source is recorded; those have no number.
Funding
How much has Acta Pharmaceuticals raised?
Rounds and backers, each sourced.
Rounds
- 2026-10-15
Seed · $24M raised3
Led by Not recorded
Backers
No backer recorded. Backers are the lead investors a sourced round names.
Opportunities For accredited investors
Ways to invest in this company through an Alphaneo vehicle, when one exists. This section looks the same on every company page until you have an accredited profile.
Opportunities, terms and data rooms are shown to accredited investors. Creating a profile takes two minutes, and you’re notified first when anything opens.
No live opportunities right now. Accredited investors are notified first when one opens.
Create an accredited profileA vehicle is never smaller than $1,000,000.
People
Who founded and leads Acta Pharmaceuticals?
Names and titles only, each sourced.
Sources
Every claim on this page traces to one of these. The numbers match the citations above.
- 1Contact – ACTA Pharmaceuticals opens in a new tabHeadquarters · accessed Oct 16, 2026
- 2Team – ACTA Pharmaceuticals opens in a new tabPeople · accessed Oct 16, 2026
- 3Acta Pharmaceuticals closes $24 million in seed financing for Alzheimer’s disease pipeline targeting early intervention and prevention opens in a new tabFounded, Stage, Total raised, Funding · accessed Oct 16, 2026
- 4ACTA Pharmaceuticals – Advancing Alzheimer’s Treatment and Prevention. opens in a new tabWebsite · accessed Oct 16, 2026